Lakefront Biotherapeutics (LKFT) Current Deferred Revenue (2014 - 2026)
Lakefront Biotherapeutics (LKFT) reported Current Deferred Revenue of $37463.9 for Q1 2026, down 99.98% year-over-year from $242.6 million in Q1 2025, and up 0.58% quarter-over-quarter from $37249.4 in Q4 2025.
Lakefront Biotherapeutics (LKFT) Current Deferred Revenue (2014 - 2026) Analysis & Trends
Lakefront Biotherapeutics (LKFT) has 13 years of Current Deferred Revenue data on file, last reported at $37463.9 in Q1 2026.
- Current Deferred Revenue for Q1 2026 came in at $37463.9, down 99.98% year-over-year; the trailing twelve-month figure through Mar 2026 was $37463.9 (down 99.98% YoY), and the FY2025 annual result was $37249.4, down 99.99% from the prior year.
- Current Deferred Revenue advanced to $37463.9 in Q1 2026 per LKFT's latest filing, from $37249.4 in the prior quarter.
- Over five years, Current Deferred Revenue peaked at $469.3 million in Q1 2022 and troughed at $37249.4 in Q4 2025.
- A 5-year average of $258.9 million and a median of $260.6 million in 2025 frame the typical range for Current Deferred Revenue.
- On a YoY basis, Current Deferred Revenue climbed as much as 6.08% in 2025 and fell as far as 99.99% in 2025.
- A 5-year view of Current Deferred Revenue shows it stood at $373.0 million in 2022, then dropped by 26.08% to $275.7 million in 2023, then retreated by 9.9% to $248.4 million in 2024, then sank by 99.99% to $37249.4 in 2025, then gained by 0.58% to $37463.9 in 2026.
- Business Quant data shows LKFT's Current Deferred Revenue at $37463.9 in Q1 2026, $37249.4 in Q4 2025, and $269.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - |
| 10 | Lakefront Biotherapeutics | 9.64 Bn | 9.64 Bn | 1.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 37,463.86 |
| Dec 31, 2025 | 37,249.39 |
| Sep 30, 2025 | 269.02 Mn |
| Jun 30, 2025 | 260.62 Mn |
| Mar 31, 2025 | 242.60 Mn |
| Dec 31, 2024 | 248.42 Mn |
| Sep 30, 2024 | 253.62 Mn |
| Mar 31, 2024 | 252.54 Mn |
| Dec 31, 2023 | 275.73 Mn |
| Sep 30, 2023 | 343.41 Mn |
| Mar 31, 2023 | 377.08 Mn |
| Dec 31, 2022 | 373.03 Mn |
| Mar 31, 2022 | 469.28 Mn |
| Dec 31, 2021 | 480.31 Mn |
| Jun 30, 2021 | 503.47 Mn |
| Dec 31, 2020 | 528.37 Mn |
| Jun 30, 2020 | 444.61 Mn |
| Mar 31, 2020 | 462.63 Mn |
| Dec 31, 2019 | 3.32 Bn |
| Sep 30, 2019 | 521.61 Mn |